A multi-center clinical trial of reduced glutathione enteric-coated capsule in the management of chronic hepatitis B
王迎昕,陈锡美,李军,胡坚方,金清龙,贺永文,张照华,王青,龚作炯
DOI: https://doi.org/10.3760/cma.j.issn.1000-6680.2013.05.004
2013-01-01
Abstract:Objective To evaluate the efficacy and safety of reduced glutathione enteric-coated capsule in the management of chronic hepatitis B.Methods A multi-center,randomized,double-blind and double-dummy,positive-and parallel-controlled trial was conducted in patients with mild or moderate chronic hepatitis B.Two hundred and four subjects were randomly divided into reduced glutathione enteric-coated capsule group (n =102) and control group (reduced glutathione tablet group,n=102).Patients in both groups were orally dosed 0.4 g three times daily for 12 weeks.There were 17 dropout cases,and finally 187 patients were available for the assessment.Difference of quantitative date was analyzed by rank sum test,and differene of measurement date was compared with analysis of variance.Results At the end of week 12,parameters of liver functions were significantly improved when compared with baseline in both reduced glutathione enteric-coated capsule group [alanine aminotransferase (ALT):64 U/L vs 134 U/L,T=-1050.5,P＜0.01; aspartate aminotransferase (AST):47 U/L vs 76 U/L,T=-1033.5,P＜ 0.01; total bilirubin (TBil):15 μmol/L vs 16 μmol/L,T=-681.0,P＜0.05; gamma-glutamyltransferase (γ-GT):38 U/L vs 47 U/L,T=-545.0,P＜0.05] and control group (ALT:72 U/L vs 122 U/L,T=-1205.5,P＜0.01; AST:51 U/L vs 72 U/L,T=-1187.5,P＜0.01; TBil:15 μmol/L vs 17 μmol/L,T=-624.5,P＜0.05; γ-GT:36 U/L vs 52 U/L,T=-776.0,P＜0.05).The rates of significant improvement and improvement in reduced glutathione enteric coated capsule group were 28.72％(27/94) and 12.77％ (12/94),respectively,and those in control group were 18.28％ (17/93) and 12.90％ (12/93),respectively.The differences between two groups were not statistically significant (x2=0.679,P＞ 0.05).The incidences of medication related adverse events were low [10.64 ％ (10/94) and 10.75 ％ (10/93) for reduced glutathione enteric-coated capsule group and control group,respectively,P＞0.05],with good safety.Conclusion Reduced glutathione enteric-coated capsule significantly decreases aminotransferase levels in chronic hepatitis B with good safety.